Lyell Immunopharma, Inc. (LYEL) Stock Grade

About Lyell Immunopharma, Inc.'s fundamentals

Lyell Immunopharma is a small-cap biotechnology company with a market capitalization of $238.7 million that reported a significant net loss in its latest annual statement, resulting in an extreme negative net margin of -762,355.6%. The company experienced steep revenue decline of 41.0% year-over-year, indicating substantial contraction in its business. As a pre-profitability biotech firm, Lyell does not pay dividends and does not have meaningful P/E or return on equity metrics, which is typical for development-stage pharmaceutical companies still investing heavily in research and drug development programs.